It has been suggested that testing AML patients for IDH mutation status is simple and should be performed universally; however, the relationship between IDH mutation status and prognosis is considerably less clear and more controversial in AML than it is in other cancers such as glioma (46, 55). This evidence concerns the gene IDH1 and acute myeloid leukemia.